# A Study to Test How Well Men Tolerate Different Doses of BI 3006337

> **NCT05076422** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 80 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 3006337
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05076422
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-18
- **Primary completion:** 2023-03-03
- **Final completion:** 2023-03-03
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05076422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05076422, "A Study to Test How Well Men Tolerate Different Doses of BI 3006337". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05076422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*